|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Financial Markets Research: ASCO Review Part II - A summary of highlights presented at the ASCO 2006 Annual Meeting |
|
|
|
|
€ 3 040,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Août 2006 |
Taille du document : |
14 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 133 pages | Novembre 2002 | Anglais
|
|
|
| Main
focus: |
oncology,cancer,carcinoma,breast cancer,...,...
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,japan,china,united kingdom,germany,canada,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pharmaceutical Mergers & Aquisitions: the third wave
160 pages | Février 1999 |
Historical assessment : The report identifies the factors that have driven the two historical waves of M&A activity, and analyses the relative importance of these factors through case studies.
795,00 €
|
|
| |
| |
Lifestyle Drugs Outlook to 2005
130 pages | Février 1999 |
Definition of lifestyle drugs : The disease, product and social characteristics that make a drug lifestyle drug.
Epidemiology : The patient potential for lifestyle drugs such as sexual dysfuncti |
795,00 €
|
| |
| |
The Generics Outlook 2001
242 pages | Février 2001 |
“By the year 2004, it is expected that the value of the total western European generics sector may have risen to $19 billion, representing almost 15% of allpharmaceuticals.
In the USA, the val |
955,00 €
|
| |
| |
The Diagnostics Outlook to 2005
130 pages | Février 1999 |
Diagnostic market : The current in vitro diagnostic (IVD) market is discussed, identifying how the market can be segmented according to country, end user, clinical speciality and disease area.
795,00 €
|
|
| |
| |
Chinese Markets for Pharmaceuticals
225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic |
3 500,00 €
|
| |
| |
The Pharmaceutical Profitability Outlook
150 pages | Février 1999 |
Is pharmaceutical profitability sustainable into the 21st century? “As the pharmaceutical industry finds itself at a crossroads, the strategic directions companies take will be pivotal in determini |
795,00 €
|
| |
| |
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused |
955,00 €
|
| |
| |
OTC Cough and Cold Remedies in Germany
15 pages | Juillet 2002 |
The German market for OTC cough and cold remedies reached a value of Euro 972 million (US$ 918 million) in 2001, up 0.4% on the previous year.
During the review period, the market grew by 9.4%, an |
198,00 €
|
| |
| |
The CNS Outlook 2000
203 pages | Octobre 2000 |
The Central Nervous System (CNS) market has shown sustained growth in 1999 with the expansion continuing to be driven by several factors.A greater understanding of the neuropharmacological mechanisms |
955,00 €
|
| |
| |
Patient Power in the Pharmaceutical Industry: The shift towards more informed, more powerful consumers of drugs
119 pages | Juin 1999 |
The dramatic rise in patient power in recent years presents a new and challenging opportunity to pharmaceutical companies, healthcare providers and governments alike.
A great need exists for ph |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Financial Markets Research: ASCO Review Part II - A summary of highlights presented at the ASCO 2006 Annual Meeting |
|
|
Introduction
ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor's comments on the most important events at the 2006 conference.
Scope
A summary of highlights presented at ASCO 2006 on Monday June 4, 2006, as well as information on related presentations from earlier in the conference
Drugs covered include Celgene's Thalomid (thalidomide) & Revlimid (lenalidomide), Genentech's Avastin (bevacizumab), Millennium's Velcade (bortezomib)
Highlights
Continuing a disappointing weekend, Nexavar was unable to show a statistically significant survival benefit in second-line metastatic renal cell carcinoma (RCC) in an update from the trial that led to its FDA approval. But, we believe that reports that Nexavar has 'failed' to show a survival benefit appear to be misleading.
We note that while data presented at ASCO has given Sutent frontrunner status in first-line therapy in RCC, results from trials examining various targeted agents have suggested that these therapies may be used sequentially in metastatic disease.
Results of numerous trials in multiple myeloma (MM) with Thalomid, Revlimid, and Velcade proved overwhelmingly positive, with high efficacy and superiority over standard regimens in both front-line and later-line settings. The optimal regimen is being evaluated in ongoing clinical trials, from which we expect data to emerge over the next two years.
Reasons to Purchase
Identify the most important events that occurred at ASCO 2006
Understand the impact of key data presentations on the potential future dynamics of the oncology market
|
|
Introduction
ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor's comments on the most important events at the 2006 conference.
Scope
A summary of highlights presented at ASCO 2006 on Monday June 4, 2006, as well as information on related presentations from earlier in the conference
Drugs covered include Celgene's Thalomid (thalidomide) & Revlimid (lenalidomide), Genentech's Avastin (bevacizumab), Millennium's Velcade (bortezomib)
Highlights
Continuing a disappointing weekend, Nexavar was unable to show a statistically significant survival benefit in second-line metastatic renal cell carcinoma (RCC) in an update from the trial that led to its FDA approval. But, we believe that reports that Nexavar has 'failed' to show a survival benefit appear to be misleading.
We note that while data presented at ASCO has given Sutent frontrunner status in first-line therapy in RCC, results from trials examining various targeted agents have suggested that these therapies may be used sequentially in metastatic disease.
Results of numerous trials in multiple myeloma (MM) with Thalomid, Revlimid, and Velcade proved overwhelmingly positive, with high efficacy and superiority over standard regimens in both front-line and later-line settings. The optimal regimen is being evaluated in ongoing clinical trials, from which we expect data to emerge over the next two years.
Reasons to Purchase
Identify the most important events that occurred at ASCO 2006
Understand the impact of key data presentations on the potential future dynamics of the oncology market
|
|
|
PPLSEN
|
|
|
|
|
